Healthy Life Forum Partners

Healthy Life Forum General Partner

Healthy Life Forum Partners

Healthy Life Forum Business Programme Partners

Healthy Life Innovative Solutions Contest Organization Partner

Healthy Life Forum Organization Partner

Healthy Life Forum Media Partners


For more than 125 years, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world’s most challenging diseases.  MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. MSD has been operating in Russia since 1991 with a focus on delivering innovative medicines and vaccines, cooperation with local manufacturers and leading medical institutions, clinical research programs, as well as medical education and information support. We use our global expertise to contribute to the development of healthcare and pharmaceutical industry in Russia.

The Skolkovo Foundation

The Skolkovo Foundation is a non-profit organization founded in September 2010 by the Russian government with the objective of accelerating Russia’s transformation from a resource-intensive to an innovation-based economy. To achieve this objective, the Foundation is overseeing the creation of the Skolkovo Innovation Center, composed of more than 1,800 high-tech startups, Skolkovo Technopark, the Skolkovo Institute of Technology (Skoltech) – a new graduate research University established in collaboration with the Massachusetts Institute of Technology – and Skolkovo city, located near Moscow. Together, these entities establish a vibrant ecosystem of technology innovation and entrepreneurship. The cumulative revenue of Skolkovo’s startups reached $2,5 billion. They brought in more than $186 million in investment, creating 27,000 jobs and filing over 1,100 patent applications along the way. By 2020 over 2 million square meters of residential and office space will be built in Skolkovo with 35,000 people working daily in the Innovation Center. 


Promsvyazbank – a universal state-owned bank (founded in 1995) – is among top-10 largest banks in Russia and designated as a systemically important financial institution by the Central Bank of Russia. More than 200,000 corporate clients (including 10,000 large corporate clients) and 2,5 million retail customers use the services and products of the Bank. PSB regional network comprises approximately 300 offices.

Novartis Group in Russia

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125 000 people of more than 140 nationalities work at Novartis around the world.

Company has more than 120 years of history in Russia. From the opening of the first pharmaceutical factory in the late 19th century up to the present day Novartis Group has always been a reliable partner for Russia in the development of health care and improvement of the patient access to quality health care services. All Company's business units and production facility are currently presented in Russia, more than 2,000 Novartis employees are working for the benefit of patients in the majority of the Russian regions.


BIOCAD is a fully integrated biotechnology company with in-house capabilities ranging from new molecules discovery to large-scale commercial manufacturing and marketing. The company has its own world-class R&D centres, pharmaceutical and biotech manufacturing sites, and performs clinical and non-clinical studies, all in compliance with the international industry standards.

Company portfolio includes more than 50 approved products, 10 of which are biologics. There are over 40 products in development: biologics, small molecules, gene and cell therapy drugs. Today BIOCAD is focused on developing original drugs – next-in-class and first-in-class – for immuno-oncology, haematology and autoimmune disease treatment.

BIOCAD has 8 international offices and subsidiaries. Company products are already marketed in 15 countries from Latin America to Africa and South East Asia and approval processes are ongoing in over 30 countries worldwide. Starting in 2021 the company will launch its original and biosimilar products in Europe and plans to enter the Chinese market in 2022.


For 130 years Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, minimally invasive medical devices, coronary stents, nutritionals and branded generic medicines. We help people with diabetes effectively manage it without painful finger pricks.

Abbott is one of the most diversified companies in healthcare. Our 103,000 colleagues serve people in more than 160 countries.

Abbott was one of the first foreign investors by opening baby nutrition manufacturing 40 years ago in the USSR. In 2014 Abbott acquired Veropharm, since then strategically executing manufacturing modernization, technology transfer and localization of medicines. Abbott’s manufacturing sites located in Volginsky of Vladimir region, Belgorod and Voronezh. In Russia Abbott employs over 3500 people.

Our company is a strategic investor and supports modern healthcare development. We strive to make quality medicines and innovative medical technologies more accessible to more people in Russia.

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda Pharmaceuticals, LLC located in Moscow, is the Russian marketing and sales organization of Takeda Pharmaceutical Company Limited, Osaka, Japan. 

Boehringer Ingelheim

Improving the health and quality of life is the main goal of the pharmaceutical company Beringer Ingelheim. The company concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. The company has been successfully operating in the Russian market for more than 25 years. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals.

The R-Pharm Group of Companies

The R-Pharm Group of Companies is one of the leaders on the Russian pharmaceutical market. Founded in 2001 by Alexey Repik, the company has a staff of more than 3,600 highly qualified specialists. The group operates throughout the Russian Federation, the CIS, the United States, Germany, and Japan, among other countries. It has more than 70 branches and representative offices. R-Pharm specializes in research and development, the production of high-tech medicines as well as the supply of laboratory equipment and medical devices. The group’s portfolio includes drugs from various pharmaceutical groups, including oncological, haematological, cardiological, immunological, antibacterial, and antiviral drugs, as well as those used in HIV therapy, organ transplantation, the treatment of multiple sclerosis, haemophilia, muscle relaxants, radiocontrast dyes, and agents used for anaesthesia.


GSK is an international pharmaceutical research company that develops and manufactures innovative medicines, vaccines, and healthcare products. Millions of people around the world use our products to help them do more, feel better, and live longer.

More than 100 GSK prescription drugs have been registered in Russia. GSK prescription drugs are used to treat diseases of the respiratory organs, infectious diseases, including HIV, diseases of the central nervous system, and also for urology, immunology, dermatology, and vaccination. GSK is one of the industry leaders in terms of investment in research in Russia.

The Association of International Pharmaceutical Manufacturers (AIPM)

The Association of International Pharmaceutical Manufacturers (AIPM) was established in 1994 and represents in the Russian Federation the leading international pharmaceutical companies – producers and developers of modern effective, safe and high-quality medicines. Today, AIPM unites more than 60 international companies that provide over 80% of the world’s pharmaceutical products and over 60% of medicines imported into the Russian Federation. AIPM members consist of both Russian and foreign pharmaceutical manufacturers. The Association itself is a member of respected Russian and international organizations, such as the Russian Union of Industrialists and Entrepreneurs (RSPP), the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA). AIPM is headed by Executive Director Vladimir Shipkov.

Pharmvestnik (‘Pharmaceutical Herald’)

Pharmvestnik (‘Pharmaceutical Herald’) is the leading specialized media covering the Russian pharmaceutical industry.

Pharmvestnik carries opinions of market leaders, leading experts, authorities and public organizations.

It covers the various sectors of the Russian pharma market and provides regulatory analysis as well as offers practical advice valuable in the pharmacist’s and HR manager’s perspective. Equal coverage is also given to all Russia’s federal districts as Pharmvestnik has regional representatives in all major cities and towns.

The Doctor TV channel

The Doctor TV channel is the first popular science and educational channel about medicine. We offer mainstream audiences a programme about medical science achievements as well as new methods for the diagnosis and treatment of diseases.

The Doctor channel presents:

–        Leading experts from Russia and around the world

–        Fundamental science and new ideas in the medicine industry

–        Innovative methods for the diagnosis and treatment of diseases

–        Modern technologies and medical equipment.

Health is a subject that concerns everyone! (Doctors United) is an educational social network for doctors. The web portal editors have prepared over 2,500 exclusive educational videos for different medical specialists. The video archive includes recorded conference reports on vital topics, video lectures by Russian and foreign PhDs in medicine, documentaries and interviews on relevant medical issues. Our web portal regularly holds webinars which provide you with a unique opportunity to ask questions online. encourages knowledge exchange, professional communication, and forming new contacts. Feel free to join us!

Medvestnik is the specialized portal for doctors and health officials. includes a news feed, a library of professional publications, the Encyclomedia medical knowledge base and the Medvestnik TV video channel.

Russian Physician Publishing House LLC

Russian Physician Publishing House publishes the following scientific magazines:

Physician – for physicians of all professions;

Nurse – for nurses;

Pharmacy – for chemists, pharmacists, manufacturers, and production engineers.

Molecular Medicine publishes the results of scientific studies on the molecular and genetic makeup of the etiology and pathogenesis of human diseases.

Sports Medicine: Science and Practice – information for sports doctors.

Biological, Medical, and Pharmaceutical Chemistry Issues.

All the magazines are included in the list of the State Commission for Academic Degrees and Titles.

Poliklinika Magazin

The professional medical magazine Poliklinika has been published since 1999. It is designed for managers and physicians working in all professions at healthcare facilities. In our magazine, you will find: information about legislative and regulatory documents in healthcare and the activities of the Russian Ministry of Health; science and practical medicine news; expert advice for healthcare facility employees; articles about new drugs and methods for their use, and medical equipment.

Poliklinika magazine is included in the Russian Science Citation Index (RISC) system and has been assigned the International Standard Serial Number ISSN 2311-2441 as its unique identifier.

The magazine is published in A4 format and has circulation of 14,000 copies.

Distribution form:

• subscription through the Rospechat agency’s catalogue;

• subscription through the editoral board;

• direct mailing to healthcare facilities;

• distribution at exhibitions.



MED-info is a unique social project that aims to promote a healthy lifestyle, boost the public’s awareness about medicine and health, educate citizens, and create a motivational system for them to maintain and improve their health and engage in health fads.

MED-info provides its readers with the latest medical and pharmaceutical news, announcements about important events, reports, exclusive interviews with prominent experts, popular science and analytical articles by physicians, investigations, and useful services. MED-info readers have the opportunity to ask physicians questions and get answers for free. MED-info experts include professional therapists, endocrinologists, oncologists, gynecologists, pediatricians, and other specialists.

“Healthcare of Russia”

“Healthcare of Russia” is the annual journal of the publishing house EuroMedia.

The most voluminous magazine for specialists in the field of medicine and pharmaceuticals in Russia. Published since 2012. Magazine for medical and pharmaceutical workers, as well as for distribution in the venues of medical and pharmaceutical exhibitions, seminars, conferences and other similar events.

In 2016, the magazine entered the Book of Records of Russia as the most voluminous publication for specialists in the field of medicine and pharmaceuticals in the Russian Federation. The magazine has repeatedly received high marks from leading specialists in the Russian medical industry.

Each journal “Healthcare of Russia” is designed for a long period and will allow you to get the most complete picture of the potential and prospects for the development of the health care system of the regions of the Russian Federation.

“Remedium” Group of Companies

“Remedium” Group of Companies renders the whole range of services for specialists in the field of medicine and pharmaceutics. For years the principle directions of activity of “Remedium”, “Rossiiskie apteki”, “Meditsinskiy Sovet”, “Ambulatory surgery”, “Aterotromboz” Group of Companies are publication of particularized periodicals, assignment of electronic databases, arrangement and implementation of measures, rent-a-rep service, organization of advertisement and PR support.

Who is Who in medicine, Federal industry magazine

The journal provides a multi-faceted dialogue on the implementation of health care programs, the development of modern medical technologies, improving organizational activities, finding effective innovative solutions, serves as a tool in personnel policy, strengthening the reputation and stimulating the best employees, ensuring the progress and professional success of domestic medicine. The journal has been published since 2003 in 6 open access formats. Choose a convenient format and join the dialogue